Why Metagenomi Therapeutics, Inc.’s (MGX) Stock Is Up 5.56%
As of Friday, April 17, Metagenomi Therapeutics, Inc.’s MGX share price has surged by 5.56%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Commentary & Analysis
Why Metagenomi Therapeutics, Inc.’s (MGX) Stock Is Down 5.04%
As of Friday, March 27, Metagenomi Therapeutics, Inc.’s MGX share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Metagenomi Therapeutics, Inc.’s (MGX) Stock Is Up 5.84%
As of Wednesday, March 25, Metagenomi Therapeutics, Inc.’s MGX share price has surged by 5.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Metagenomi Therapeutics, Inc.’s (MGX) Stock Is Down 5.68%
As of Wednesday, March 11, Metagenomi Therapeutics, Inc.’s MGX share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Metagenomi Therapeutics, Inc.’s (MGX) Stock Is Up 6.25%
As of Tuesday, March 10, Metagenomi Therapeutics, Inc.’s MGX share price has surged by 6.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | MGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44.8 | $252.6 | 15% |
|
| Shares Out (Mil) | 37.6 | 52.3 | 42% |
|
| Institutional Ownership | 63.4% | 92.1% | 40% |
|
| Float (Mil) | 25.4 | 40.2 | 33% |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 150 | 455 | 41% |
|
| Price Change (52-week) |
(47.6%) | 52.9% | 17% |
|
| Growth | MGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.520) | ($2.160) | ($2.120) | |
| Month Ago EPS | ($0.550) | ($2.110) | ($1.470) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.580) | ($2.173) | ($1.673) | |
| Year/Year Chg | (15.3%) | (8.4%) | (14.8%) | |
| Financials | MGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $22 | $38 | 14% |
|
| Net Income (TTM) (Mil) | ($86) | ($43) | 12% |
|
| EPS (TTM) | ($2.297) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($87) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $5 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $33 | $5 | 36% |
|
| Enterprise Value (Q1) (Mil) | ($56) | $180 | 1% |
|
| Valuation | MGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.33 | 2.56 | 5% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (321.0%) | 63.8% | 1% |
|
| Net Margin | (384.6%) | (67.3%) | 2% |
|
| ROA | (34.7%) | (49.8%) | 15% |
|
| ROE | (49.0%) | (55.5%) | 15% |
|
| Liabilities to Assets | 30.0% | 30.3% | 21% |
|
| F-Score | 1 | 3 | 1% |
|
Metagenomi Therapeutics, Inc. did not pass any screens on 7/31/2026.
